戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 for preventing oral premalignant lesions and second primary tumors.
2 CC patients per year will develop additional second primary tumors.
3 l of premalignant lesions, and prevention of second primary tumors.
4 ase reduce the risk of tobacco smoke-related second primary tumors.
5 ascular disease, diabetes, osteoporosis, and second primary tumors.
6 patients who are at high risk for developing second primary tumors after surgical removal of the init
7  since chemotherapy in these 68 survivors, 7 second primary tumors and 8 opportunistic infections wer
8 d for up to 90 months for the development of second primary tumors and local recurrences.
9 tance in assessing individuals for risk of a second primary tumor as well as in devising effective st
10 tologic criteria, these relapses represented second primary tumors developing in the conservatively t
11         To date, one patient has developed a second primary tumor in the aerodigestive tract.
12 ignant lesions), and tertiary (prevention of second primary tumors in previously treated patients), a
13 iously irradiated, locoregional recurrent or second primary tumors in the head and neck, and describe
14  premalignant lesions and the development of second primary tumors in those already treated for squam
15 or pack-years and other factors, and risk of second primary tumors increased by 1.5% per pack-year (H
16 the apical urethral margin and the risk of a second primary tumor of the retained urethra, all of whi
17 tween the two groups in the time to failure [second primary tumors plus local recurrences: relative r
18 arcinoma of the head and neck (SCCHN) or new second primary tumor (SPT) in a previous radiation field
19                           The development of second primary tumors (SPTs) in patients with head and n
20 ontrolled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected n
21 N-alpha) for preventing tumor recurrence and second primary tumors (SPTs) of skin squamous cell carci
22 e II adjuvant trial to prevent recurrence or second primary tumors (SPTs) using 13-cRA, IFN-alpha, an
23                           The 3-year rate of second primary tumors was 7% with MPR-R, 7% with MPR, an
24 arcinoma are at high risk for development of second primary tumors, which pose the main threat to sur

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。